Thrombophilic Risk Factors in Pediatric Patients Diagnosed at the Ha'Emek Medical Center
NCT ID: NCT00736008
Last Updated: 2011-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2008-05-31
2009-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The results, the treatment given, and the outcome of the patients will be summarized.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
NCT00412464
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
NCT06281327
Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
NCT04737850
A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia
NCT03806556
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
NCT04516967
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Patients with thromboembolic events
Observational
Data summary only
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observational
Data summary only
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria:Patients with insufficient data records.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HaEmek Medical Center, Israel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Koren Ariel
Head of Pediatric Hematology Unit and Pediatric Dpt B
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carina Levin, MD
Role: PRINCIPAL_INVESTIGATOR
Pediatric Hematology Unit - Ha'Emek Medical Center - Afula - 18101 - Israel
Ayala Mari, Student
Role: PRINCIPAL_INVESTIGATOR
Pediatric Dpt B - Ha'Emek Medical Center - Afula - Israel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pediatric Hematology Unit - Ha'Emek Medical Center
Afula, Afula, Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0020-08-EMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.